FH and hereditary leiomyomatosis and renal cell cancer: Kerins et al. [52] conducted drug sensitivity screening using the NCL-60 cancer cell line, focusing on FH inactivation to develop therapeutic agents for HLRCC, and identified drug sensitivity gene signatures according to their sensitivity to certain compounds.